Fate Therapeutics registers Phase 1/2 trial of FT839 across five autoimmune diseasesSep 2Trial updateFate TherapeuticsFT839
Fate Therapeutics doses first lupus nephritis patient in Phase 2 FT819 trial, clears FT839 INDAug 13Quarterly updateFate TherapeuticsFT819
Sign inSign in